Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet (scientific article (publication date: 30 October 2009))

cites work (P2860)

Q28072539	'Acute myeloid leukemia: a comprehensive review and 2016 update'
Q36067419	18α-Glycyrrhetinic Acid Induces Apoptosis of HL-60 Human Leukemia Cells through Caspases- and Mitochondria-Dependent Signaling Pathways.
Q36944013	2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.
Q91669258	A 10-Long Non-Coding RNA-Based Expression Signature as a Potential Biomarker for Prognosis of Acute Myeloid Leukemia
Q50538514	A 17-gene stemness score for rapid determination of risk in acute leukaemia.
Q47307310	A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.
Q40226406	A 4-gene expression score associated with high levels of Wilms Tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia
Q37672497	A 75-year-old woman with thoracic spinal cord compression and chloroma (granulocytic sarcoma)
Q40173412	A Case Report: Acute Myeloid Leukemia (FAB M7).
Q92620231	A Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology
Q28597169	A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis
Q35981082	A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia
Q52621674	A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Q36157664	A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
Q53043418	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.
Q40686643	A Rare Case of Acute Myeloid Leukemia with a t(2;3) Chromosomal Translocation Characterized by Thrombophilia and Chemoresistance
Q89940495	A Remarkable Remission: Treating HMA Refractory Transforming MDS with Single-Agent Low-Dose Cytarabine Leading to an Ongoing Six-Year OS
Q36423882	A Review of Mathematical Models for Leukemia and Lymphoma
Q42764236	A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators
Q88312758	A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission
Q91672285	A case of acute megakaryoblastic leukaemia (FAB M7), a rare type of acute myeloid leukemia (AML), in a teenager
Q42842995	A case of acute myeloid leukemia (AML) with an unreported combination of chromosomal abnormalities: gain of isochromosome 5p, tetrasomy 8 and unbalanced translocation der(19)t(17;19)(q23;p13).
Q37429209	A clinical challenge: Treatment of acute myeloid leukemia in a Jehovah's Witness
Q35885317	A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia
Q36653102	A comparative study of idarubicin 12 mg/m(2) and 8 mg/m(2) combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients
Q36858928	A de novo acute myeloid leukemia (AML-M4) case with a complex karyotype and yet unreported breakpoints
Q48262712	A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia.
Q38695117	A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.
Q48267537	A hospital based retrospective study of factors influencing therapeutic leukapheresis in patients presenting with hyperleukocytic leukaemia
Q41872131	A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia
Q35794439	A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Q83434939	A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study
Q56517348	A new adult AML case with an extremely complex karyotype, remission and relapse combined with high hyperdiploidy of a normal chromosome set in secondary AML
Q42379001	A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression
Q42399828	A novel mechanism of NPM1 cytoplasmic localization in acute myeloid leukemia: the recurrent gene fusion NPM1-HAUS1.
Q33826848	A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Q47590567	A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Q89779296	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia
Q57169390	A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia
Q47563820	A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia
Q64125995	A phase 2 study incorporating sorafenib into the chemotherapy for older adults with -mutated acute myeloid leukemia: CALGB 11001
Q33392683	A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
Q64967606	A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
Q50043852	A phase I study of CPI-613 in combination with high dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia.
Q49188547	A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
Q34353111	A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.
Q33630851	A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia
Q40614153	A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
Q54281304	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.
Q36892590	A polymorphism in the 3'-untranslated region of the NPM1 gene causes illegitimate regulation by microRNA-337-5p and correlates with adverse outcome in acute myeloid leukemia.
Q40780156	A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Q96609997	A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy
Q42266529	A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia
Q46744333	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia
Q58414303	A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia
Q97423271	A rare case of acute myeloid leukemia with t(12;19)(q13;q13)
Q38924940	A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy.
Q37474559	A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia
Q45917057	A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia.
Q37648114	A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice
Q37228655	A three-gene expression-based risk score can refine the European LeukemiaNet AML classification.
Q89100184	A three‑lncRNA signature for prognosis prediction of acute myeloid leukemia in patients
Q97517849	A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis
Q90738631	A-kinase interacting protein 1 might serve as a novel biomarker for worse prognosis through the interaction of chemokine (C-X-C motif) ligand 1/chemokine (C-X-C motif) ligand 2 in acute myeloid leukemia
Q41276978	ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate
Q38724266	ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML.
Q40852245	ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome
Q28484890	AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin
Q34212654	AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias
Q41195376	AML versus ICU: outcome of septic AML patients in an intensive care setting
Q27851909	ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome
Q27851679	ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Q35146279	ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group
Q35691393	Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.
Q28076011	Aberrant splicing and drug resistance in AML
Q34045687	Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells
Q38526934	Acute Myeloid Leukemia With Recurrent Genetic Abnormalities Other Than Translocations.
Q51741035	Acute Myeloid Leukemia as the Main Cause of Pancytopenia in Iranian Population.
Q97067778	Acute Myeloid Leukemia in Qatar (2010-2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes
Q26766719	Acute Myeloid Leukemia: A Concise Review
Q38948650	Acute Myeloid Leukemia: How Do We Measure Success?
Q34655572	Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Q34632079	Acute myelogenous leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: retrospective analysis of molecular genetic evaluation
Q52318200	Acute myelogenous leukemia in adolescents and young adults.
Q47648907	Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche
Q39400164	Acute myeloid leukaemia genomics.
Q34327218	Acute myeloid leukaemia in adults
Q37840260	Acute myeloid leukaemia in the elderly: a review
Q47432401	Acute myeloid leukaemia.
Q36914091	Acute myeloid leukaemia: optimal management and recent developments
Q35988201	Acute myeloid leukemia and translocation (8; 16) (p11; p13), the first Moroccan case of a distinct clinical-biological entity
Q55292778	Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?
Q38681408	Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis
Q38026008	Acute myeloid leukemia in older adults
Q39311595	Acute myeloid leukemia in the elderly (age 70 yr or older): long-term survivors.
Q38124066	Acute myeloid leukemia in the elderly: do we know who should be treated and how?
Q36849666	Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification
Q38269553	Acute myeloid leukemia in the pregnant patient
Q35980291	Acute myeloid leukemia in the real world: why population-based registries are needed
Q42761055	Acute myeloid leukemia masquerading as hepatocellular carcinoma
Q88735032	Acute myeloid leukemia therapy and the chosen people
Q37318679	Acute myeloid leukemia with adverse cytogenetic risk
Q40519126	Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.
Q47107319	Acute myeloid leukemia with e1a2 BCR-ABL1 fusion gene: two cases with peculiar molecular and clinical presentations.
Q42708639	Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum
Q38027047	Acute myeloid leukemia with normal cytogenetics
Q41973082	Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications
Q37739860	Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis
Q38644941	Acute myeloid leukemia--major progress over four decades and glimpses into the future
Q46651101	Acute myeloid leukemia. Genetic diagnostics and molecular therapy
Q27851694	Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management
Q38092771	Acute myeloid leukemia: 2013 update on risk-stratification and management
Q34665691	Acute myeloid leukemia: 2014 update on risk-stratification and management
Q38897289	Acute myeloid leukemia: 2016 Update on risk-stratification and management
Q37221579	Acute myeloid leukemia: advancing clinical trials and promising therapeutics
Q38015336	Acute myeloid leukemia: focus on novel therapeutic strategies.
Q35054850	Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná.
Q40114215	Acute myeloid leukemia: update in diagnosis and treatment in Brazil.
Q39279196	Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012.
Q94541412	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results
Q95933763	Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years
Q61813975	Adhesion Deregulation in Acute Myeloid Leukaemia
Q34312351	Advances in treating acute myeloid leukemia
Q42943348	Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype.
Q35863989	Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation
Q52855083	Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.
Q36333552	Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation
Q27851713	Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
Q58023660	Akute Leukämien des Erwachsenen
Q37325012	Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors
Q36151586	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study
Q83427652	Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity
Q44380116	Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).
Q52718440	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.
Q36914475	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Q58554859	Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia
Q47135533	Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India
Q38207595	Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions
Q35811893	Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile
Q64109318	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study
Q38248427	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective
Q41532867	Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations
Q46384069	Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR.
Q45324089	Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation
Q37118214	Allogeneic hematopoietic stem cell transplantation for patients with acute leukemia
Q37842488	Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations
Q54282566	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy.
Q48568744	Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Q42765065	Allogeneic stem cell transplantation for acute myeloid leukemia
Q38199056	Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?
Q52870483	Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome.
Q59603024	Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (
Q26996818	Allogeneic stem cell transplantation in first complete remission
Q91709978	Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT
Q35082499	Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial
Q87901185	Allogeneic transplantation in primary refractory AML
Q46515733	Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance
Q89777956	Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1
Q38161965	Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.
Q64261176	Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice
Q37876908	Amonafide: a potential role in treating acute myeloid leukemia
Q38607968	An Integrative multi-lineage model of variation in leukopoiesis and acute myelogenous leukemia.
Q64229454	An Unusual Cause of Epistaxis: Paranasal Sinus Myeloid Sarcoma
Q38285621	An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia.
Q50566510	An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts.
Q42376557	An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia
Q35141163	An integrated approach of gene expression and DNA-methylation profiles of WNT signaling genes uncovers novel prognostic markers in acute myeloid leukemia.
Q39475017	An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
Q26776396	An update of current treatments for adult acute myeloid leukemia
Q47137221	Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia
Q27026520	Animal models of leukemia: any closer to the real thing?
Q42923390	Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia
Q35146288	Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
Q34426965	Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy.
Q37603441	Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.
Q30637447	AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells
Q36932014	Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
Q38700209	Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?
Q64243249	Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia
Q57171122	Antiproliferative effect of upregulation of hsa-let-7c-5p in human acute erythroleukemia cells
Q98386325	Antiproliferative effects of L-asparaginase in acute myeloid leukemia
Q99566343	Apolipoprotein C2 - CD36 Promotes Leukemia Growth and Presents a Targetable Axis in Acute Myeloid Leukemia
Q47102086	Application of the AMLprofiler Diagnostic Microarray in the South African Setting.
Q36938430	Appropriate Clinical Strategies for Breast Cancer Coexisting with Acute Myeloid Leukemia in the Genomic-Molecular Era: A Case Report
Q49433861	Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype.
Q35189447	Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis
Q35753087	Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.
Q91666717	Association between TLR2 and TLR4 Expression and Response to Induction Therapy in Acute Myeloid Leukemia Patients
Q90562448	Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia
Q33873844	Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.
Q37216232	Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes
Q55283900	Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
Q50078399	Association of mutations with morphologic dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities.
Q39518428	Autologous Hematopoietic Stem Cell Transplantation for Adults With Acute Myeloid Leukemia.
Q38090612	Autologous Stem Cell Transplantation in elderly Acute Myeloid Leukemia
Q50919144	Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission.
Q38568355	Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects
Q31114708	Automated Assessment of Disease Progression in Acute Myeloid Leukemia by Probabilistic Analysis of Flow Cytometry Data
Q62516277	Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia
Q33752594	Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting
Q54297620	Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
Q33405278	Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
Q51111341	Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report.
Q38983626	Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
Q35835657	Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.
Q36804633	Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
Q41161466	Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Q36692756	Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Q34541748	BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Q40862157	BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4.
Q34318280	Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia
Q53702234	Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
Q33828078	Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
Q96128198	Bioinformatics and experimental studies of anti-leukemic activity from 6-gingerol demonstrate its role in p53 mediated apoptosis pathway
Q38537879	Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells.
Q38761783	Biology and relevance of human acute myeloid leukemia stem cells
Q38526017	Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology
Q59807289	Biomodulatory Treatment With Azacitidine, All- Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis
Q90375321	Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy
Q38844669	Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches
Q54016828	Blood transfusion for patients with newly diagnosed acute myeloid leukaemia undergoing induction chemotherapy in a large medical centre in China: a retrospective analysis.
Q33409558	Blue toes and a new pair of shoes--challenges in diagnosis and treatment of acute myelogenous leukemia
Q92636244	Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML
Q54660373	Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature.
Q40445337	Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia
Q39071892	Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.
Q91813300	Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia
Q39132424	Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.
Q36753274	Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines
Q38952815	Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia
Q55386407	Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis.
Q34046624	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Q36153495	Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission.
Q37587956	CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
Q49168672	CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
Q91666415	CD105 (Endoglin) as negative prognostic factor in AML
Q40118769	CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine
Q86046497	CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT
Q87912115	CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine
Q36545966	CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Q36497247	CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling
Q38884580	CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis
Q33573806	CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features
Q64934185	CEBPE expression is an independent prognostic factor for acute myeloid leukemia.
Q51510125	CHK1 as a therapeutic target to bypass chemoresistance in AML.
Q48229854	CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?
Q93051409	CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells
Q37299309	CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia
Q35177432	Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?
Q55325572	Can we forecast induction failure in acute myeloid leukemia?
Q54364092	Case study interpretation--Fort Lauderdale: Case 3.
Q39147866	Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
Q57384752	Cellular origin of prognostic chromosomal aberrations in AML patients
Q34629112	Central nervous system involvement at first relapse in patients with acute myeloid leukemia
Q36483114	Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation
Q50859525	Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups.
Q45332610	Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Q41476969	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias
Q48305735	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Q41928869	Characteristics of De Novo Acute Myeloid Leukemia Patients in Palestine: Experience of An-Najah National University Hospital
Q51033194	Characterization and analysis of the outcome of adults with acute myeloid leukemia treated in a Brazilian University hospital over three decades.
Q59194228	Characterization and prognostic significance of mitochondrial DNA variations in acute myeloid leukemia
Q98725872	Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells
Q55025524	Characterization of NPM1, FLT3, and IDH1 mutations in adult patients with acute myeloid leukemia: a Brazilian cohort study.
Q36715925	Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol
Q38747513	Characterization of hsa_circ_0004277 as a New Biomarker for Acute Myeloid Leukemia via Circular RNA Profile and Bioinformatics Analysis
Q45250906	Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.
Q64245424	Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
Q38044772	Chromosomal aberrations and fusion genes in myeloid malignancies
Q33822055	Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance).
Q49989317	Classification and risk assessment in AML: integrating cytogenetics and molecular profiling.
Q33781150	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
Q47128524	Clinical Assessment and Diagnosis of Germline Predisposition to Hematopoietic Malignancies: The University of Chicago Experience
Q49338306	Clinical Features and Outcomes of 666 Cases with Therapy-Related Myelodysplastic Syndrome (t-MDS).
Q38831810	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
Q38904250	Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders
Q89994575	Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study
Q42705413	Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.
Q53308704	Clinical and laboratory characteristics of acute myeloid leukaemia (AML) at relapse and the risk of acute incapacitation.
Q37331218	Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations
Q35900361	Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms
Q48121119	Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia
Q34340438	Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
Q36557537	Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.
Q47936319	Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients
Q50631404	Clinical impact of SNP of P53 genes pathway on the adult AML patients.
Q41993143	Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia.
Q33572303	Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial
Q39653218	Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia
Q37622957	Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia
Q53397583	Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia.
Q57898941	Clinical manifestations and diagnosis
Q35265946	Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Q34226754	Clinical relevance of mutant NPM1 and CEBPA in patients with acute myeloid leukaemia - preliminary report
Q37065843	Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients
Q41693113	Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies
Q38031146	Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group
Q33746130	Clinical study on prospective efficacy of all-trans Acid, realgar-indigo naturalis formula combined with chemotherapy as maintenance treatment of acute promyelocytic leukemia
Q33968321	Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation
Q41474323	Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.
Q37429911	Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.
Q60050027	Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC
Q96683590	Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy
Q93067058	Clonal evolution of acute myeloid leukemia from diagnosis to relapse
Q64071463	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Q56968572	Clonal heterogeneity of -ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia
Q39888679	Close correlation of copy number aberrations detected by next-generation sequencing with results from routine cytogenetics in acute myeloid leukemia
Q57898900	Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Q61811335	Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy
Q58779455	Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
Q34348102	Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia
Q36925156	Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia
Q83436488	Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia
Q34620456	Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis
Q44824037	Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience
Q53001093	Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.
Q39601810	Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio
Q46888442	Comparing leukapheresis protocols for an AML patient with symptomatic leukostasis
Q51704129	Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.
Q33830964	Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
Q34627218	Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation
Q46788345	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of E
Q48199548	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia
Q34630588	Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission
Q28546572	Complementation of the Yeast Model System Reveals that Caenorhabditis elegans OCT-1 Is a Functional Transporter of Anthracyclines
Q45221235	Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia
Q55404461	Complex Karyotype in Hematological Diseases: A 6-Year Single Centre Study from Pakistan.
Q33421005	Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
Q41197435	Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia
Q59330143	Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs/ROS/Trx1 signalling pathway
Q44467514	Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients
Q33758306	Comprehensive mutational profiling of core binding factor acute myeloid leukemia
Q37575953	Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis
Q40147710	Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy
Q40197450	Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
Q35647641	Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.
Q38229633	Conditioning regimens in acute myeloid leukemia
Q90253675	Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy
Q36107268	Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study
Q35040043	Connexin expression in human acute myeloid leukemia cells: identification of patient subsets based on protein and global gene expression profiles
Q36633055	Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life
Q39337506	Copy-number analysis identified new prognostic marker in acute myeloid leukemia
Q92587525	Core Data Elements in Acute Myeloid Leukemia: A Unified Medical Language System-Based Semantic Analysis and Experts' Review
Q37084121	Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A.
Q57483591	Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
Q64276608	Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions
Q34604460	Current knowledge and future research directions in treatment-related second primary malignancies
Q40256523	Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy
Q35146284	Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia
Q39732854	Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study
Q39002065	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis
Q57058970	Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Q39414681	Cytokine Release Patterns in Mixed Lymphocyte Culture (MLC) of T-Cells with Dendritic Cells (DC) Generated from AML Blasts Contribute to Predict anti-Leukaemic T-Cell Reactions and Patients' Response to Immunotherapy
Q33703046	Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
Q45397622	Cytological characterization of murine bone marrow and spleen hematopoietic compartments for improved assessment of toxicity in preclinical gene marking models
Q37349113	Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia
Q90028993	Cytotoxic therapy in acute myeloid leukemia: not quite dead yet
Q35640809	DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acu
Q47132650	DNA damage in acute myeloid leukemia patients of Northern Mexico
Q37797467	DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights
Q34661033	DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
Q27851689	DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
Q38282093	DNMT3A: the DioNysian MonsTer of acute myeloid leukaemia.
Q37675217	DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells
Q37166721	Daunorubicin, cytarabine, and cladribine regimen plus radiotherapy and donor lymphocyte infusion for extramedullary relapse of acute myeloid leukemia after hematopoietic stem cell transplantation
Q54336601	De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Q36304111	Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells.
Q41104655	Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Gro
Q50463311	Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study.
Q33407030	Decitabine: a review of its use in older patients with acute myeloid leukaemia
Q36554393	Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes
Q41708770	Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia
Q26772235	Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies
Q52896167	Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission.
Q34516262	Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice
Q41688469	Dendritic cells in bone marrow at diagnosis and after chemotherapy in adult patients with acute myeloid leukaemia
Q28538139	Deregulation of mitochondrial ATPsyn-β in acute myeloid leukemia cells and with increased drug resistance
Q39188673	Deregulation of protein phosphatase expression in acute myeloid leukemia
Q38918850	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
Q33795203	Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes
Q53791265	Detection of clonal heterogeneity and targetable mutations in myeloid sarcoma by high-throughput sequencing.
Q37999070	Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes
Q47774723	Determinants of 1-year survival in critically ill acute leukemia patients: a GRRR-OH study
Q54958123	Developing and piloting an instrument to prioritize the worries of patients with acute myeloid leukemia.
Q37493869	Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery
Q47648441	Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality
Q52673676	Development and Validation of a Novel RNA Sequencing-Based Prognostic Score for Acute Myeloid Leukemia.
Q90160549	Development and validation of a 10-gene prognostic signature for acute myeloid leukaemia
Q37076434	Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies
Q48142237	Development of a NanoString assay to detect leukemogenic fusion transcripts in acute myeloid leukemia
Q38103753	Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?
Q88007476	Dexamethasone in hyperleukocytic acute myeloid leukemia
Q64119614	Di--lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity
Q38240563	Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.
Q38608903	Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification
Q37624593	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Q39285462	Diagnostic & prognostic role of microRNAs in paediatric acute myeloid leukaemia.
Q57898947	Diagnostic criteria, classification, and prognosis of acute leukemias
Q46516275	Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients
Q92242805	Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience
Q26991736	Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
Q37699220	Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation
Q52608845	Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia.
Q37079676	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.
Q47353129	Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.
Q28749564	Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia
Q37188719	Distress in patients with acute leukemia: a concept analysis
Q27853019	Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
Q85934289	Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML
Q27851686	Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.
Q53804314	Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?
Q34380060	Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia
Q34502042	Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
Q38666159	Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?
Q37888956	Drosophila: a model for studying genetic and molecular aspects of haematopoiesis and associated leukaemias
Q47284112	Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.
Q38893052	Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase
Q36946572	Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia
Q36734783	EM23, A Natural Sesquiterpene Lactone from Elephantopus mollis, Induces Apoptosis in Human Myeloid Leukemia Cells through Thioredoxin- and Reactive Oxygen Species-Mediated Signaling Pathways
Q87851748	EQUATOR-Oncology: reducing the latitude of cancer trial design and reporting
Q33772607	Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia
Q34167404	Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study
Q43555651	Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.
Q90497302	Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm
Q92915912	Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial
Q60043878	Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia
Q34047867	Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells
Q37252482	Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia
Q52726355	Effect of High VEGF-C mRNA Expression on Achievement of Complete Remission in Adult Acute Myeloid Leukemia.
Q33968372	Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy
Q42384543	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia
Q38657161	Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients.
Q33400617	Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Q91699013	Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients
Q51146764	Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML).
Q33434711	Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia
Q41530049	Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis
Q57073560	Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis
Q34543909	Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program
Q41175826	Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia
Q38917137	Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
Q37429089	Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).
Q38003665	Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial
Q38078423	Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia
Q38803880	Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia.
Q38785380	Emerging cell cycle inhibitors for acute myeloid leukemia
Q47670541	Emerging molecular predictive and prognostic factors in acute myeloid leukemia
Q38818726	Emerging strategies for the treatment of older patients with acute myeloid leukemia.
Q38401664	Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication
Q38435352	Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets
Q41133468	Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells
Q43234215	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG.
Q38674045	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Q47120346	Enforced GFI1 expression impedes human and murine leukemic cell growth
Q39285841	Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making
Q47138685	Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).
Q38264968	Epigenetic alterations in acute myeloid leukemias
Q37635209	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
Q34350209	Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia
Q58814184	Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML
Q50226456	Establishment and Characterization of Long-Term Cultures Derived from Primary Acute Myeloid Leukemia Cells for HDAC Inhibitor Research.
Q37342223	Esterase D and gamma 1 actin level might predict results of induction therapy in patients with acute myeloid leukemia without and with maturation
Q39200282	Euphorbia formosana root extract induces apoptosis by caspase-dependent cell death via Fas and mitochondrial pathway in THP-1 human leukemic cells.
Q42616605	European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
Q40393514	Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy
Q83682066	Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML
Q35886215	Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy
Q92570562	Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)
Q37318667	Evaluation of prognostic factors in patients with relapsed AML: Clonal evolution versus residual disease
Q38179026	Evolving treatment strategies in patients with high-risk acute myeloid leukemia
Q57808500	Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC
Q36582324	Examination of the FLT3 and NPM1 mutational status in patients with acute myeloid leukemia from southeastern Poland.
Q51089294	Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells.
Q38973410	Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
Q36254052	Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients
Q92284294	Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells
Q34831106	Expression and prognostic impact of lncRNAs in acute myeloid leukemia
Q55365672	Expression levels of long non-coding RNAs are prognostic for AML outcome.
Q51656832	Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML.
Q54211664	Expression of Eph A4, Eph B2 and Eph B4 receptors in AML.
Q40790764	Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis
Q41225296	Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age.
Q87399852	Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation
Q42515217	Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression
Q49499257	Expression of some ATP-binding cassette transporters in acute myeloid leukemia.
Q53769196	Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
Q64092324	Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900
Q90989428	Extramedullary relapses of acute leukemias after allogeneic hematopoietic stem cell transplantation: clinical features, cumulative incidence, and risk factors
Q43188286	FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION.
Q35048217	FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
Q91845843	FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Q27028163	FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
Q33856839	FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
Q28289859	FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations
Q54243631	FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia.
Q52902952	FLT3-ITD mutations do not impact the outcome of patients allografted with partial T-cell depleted grafts for AML with normal cytogenetics in first complete remission.
Q34890418	FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype
Q89747558	FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML
Q39031946	Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Q35285004	Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy
Q36022536	Favorable clinical outcome and unique characteristics in association with Twist1 overexpression in de novo acute myeloid leukemia
Q34541052	Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study
Q94299741	Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country
Q53109363	Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach.
Q92887026	Fertility preservation from the point of view of hematopoietic cell transplant specialists-a worldwide-web-based survey analysis
Q26825765	Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy
Q47829263	Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia.
Q85377254	Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy
Q40528087	Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study
Q50257254	Fluorescent In Situ Hybridization in Suspension by Imaging Flow Cytometry.
Q42750992	Four cases of chronic myelogenous leukemia in mixed phenotype blast phase at initial presentation mimicking mixed phenotype acute leukemia with t(9;22).
Q58415977	Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association
Q33412354	Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse
Q39067366	Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Q37249351	Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission
Q35717852	Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia
Q39386021	Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia
Q52560331	From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia.
Q38767583	Frontline treatment of acute myeloid leukemia in adults
Q38917587	Fruit extract from a Sechium edule hybrid induce apoptosis in leukaemic cell lines but not in normal cells
Q90269165	Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
Q33737486	Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).
Q39332914	Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
Q28547905	G2/M Cell Cycle Arrest and Tumor Selective Apoptosis of Acute Leukemia Cells by a Promising Benzophenone Thiosemicarbazone Compound
Q33717707	GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
Q40086982	GATA3 rs3824662 gene polymorphism as possible risk factor in a cohort of Egyptian patients with pediatric acute lymphoblastic leukemia and its prognostic impact.
Q40022463	GFI1 as a novel prognostic and therapeutic factor for AML/MDS.
Q91774040	Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
Q44462005	Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia
Q33558088	Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
Q37910260	Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia
Q47136441	Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia
Q91643172	Gene coexpression network analysis revealed biomarkers correlated with blast cells and survival in acute myeloid leukemia
Q59793120	Gene expression of , , , and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin
Q35302035	Gene expression profiles associated with pediatric relapsed AML.
Q37858877	Gene expression profiling in MDS and AML: potential and future avenues.
Q47235517	Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
Q34347096	Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia
Q34647741	Gene mutations and molecularly targeted therapies in acute myeloid leukemia.
Q38077505	Gene mutations of acute myeloid leukemia in the genome era.
Q55025720	Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.
Q38044773	Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?
Q38509706	Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia
Q39942266	Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis
Q34221312	Genome wide analysis of acute myeloid leukemia reveal leukemia specific methylome and subtype specific hypomethylation of repeats.
Q27853389	Genomic Classification and Prognosis in Acute Myeloid Leukemia
Q29615735	Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia
Q38223490	Genomic characterization of acute leukemias
Q33939071	Genomic imbalances are confined to non-proliferating cells in paediatric patients with acute myeloid leukaemia and a normal or incomplete karyotype
Q37075666	Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes
Q47903598	Gingival enlargement in a pregnant woman with acute monocytic leukaemia: a case report
Q40254512	Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia
Q35940547	Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy.
Q27027798	Granulocytic sarcoma: a systematic review
Q38920692	Great expectations in acute myeloid leukemia
Q92581870	HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/β-catenin signaling
Q36336147	HO-1, RET and PML as possible markers for risk stratification of acute myelocytic leukemia and prognostic evaluation
Q38753227	HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
Q43065853	HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy
Q92918139	Haploidentical, Unmanipulated Granulocyte Colony-Stimulating Factor (G-CSF)-Primed Peripheral Blood Stem Cell Transplants for Acute Myeloid Leukemia (AML) in Remission: A Single Center Experience
Q35564902	Health care utilization and end-of-life care for older patients with acute myeloid leukemia
Q48467983	Health related quality of life and impact of infectious comorbidity in outpatient management of patients with acute leukemia.
Q53543462	Health-Related Quality of Life of Patients with Acute Myeloid Leukemia: A Systematic Literature Review.
Q38222563	Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?
Q37216297	Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia
Q36961604	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients
Q58719438	Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity
Q90441706	Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial
Q33841129	Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.
Q57143658	Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death
Q60932672	Hif-1α Deletion May Lead to Adverse Treatment Effect in a Mouse Model of MLL-AF9-Driven AML
Q47156797	High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients
Q35629275	High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials
Q49615274	High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy.
Q37510247	High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.
Q41670609	High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia
Q92567745	High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia
Q35659664	High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan
Q42285092	High Prevalence of Vitamin D Deficiency in Newly Diagnosed Acute Myeloid Leukemia Patients and Its Adverse Outcome
Q54517330	High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
Q35988637	High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly
Q91276827	High expression levels of SMAD3 and SMAD7 at diagnosis predict poor prognosis in acute myeloid leukemia patients undergoing chemotherapy
Q47283332	High expression of FLT3 is a risk factor in leukemia
Q33623126	High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia
Q53436427	High expression of OCT4 is frequent and may cause undesirable treatment outcomes in patients with acute myeloid leukemia.
Q35741669	High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia
Q43057948	High expression of transcription factor 4 (TCF4) is an independent adverse prognostic factor in acute myeloid leukemia that could guide treatment decisions
Q38809840	High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients
Q39283692	High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in FLT3 internal tandem duplication (ITD) negative patients in adult acute myeloid leukaemia: A prospective pilot study from India
Q36545112	High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis
Q44662780	High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.
Q41478883	High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Q87823188	High-dose idarubicin plus busulfan as conditioning regimen to autologous stem cell transplantation: promising post-remission therapy for acute myeloid leukemia in first complete remission?
Q35849281	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations
Q42847819	High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia
Q33393381	Histamine dihydrochloride: in the management of acute myeloid leukaemia
Q48227196	History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
Q45111985	Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial
Q88890106	How I treat older patients with acute myeloid leukemia
Q37960820	How to manage high-risk acute myeloid leukemia
Q37351908	Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia
Q39706444	Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia
Q58481777	Hyperdiploidy with 49–65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome
Q38126922	Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia
Q39038221	Hyperleukocytosis and leukostasis: management of a medical emergency
Q92091391	Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine
Q24186284	Hypomethylating agents for adult patients with acute myeloid leukaemia
Q24234645	Hypomethylating agents for adult patients with acute myeloid leukaemia
Q88446399	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Q39014493	Hypothesis: Tim-3/galectin-9, a new pathway for leukemia stem cells survival by promoting expansion of myeloid-derived suppressor cells and differentiating into tumor-associated macrophages
Q90654871	IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics
Q33897586	IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Q28066926	IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
Q44928836	IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation
Q42415934	IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications
Q42867437	IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status.
Q36379310	IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia.
Q57927278	IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML
Q24200407	Idarubicin compared to other anthracyclines for treatment of newly diagnosed acute myeloid leukaemia
Q36716744	Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.
Q92828677	Identification of CD318 (CDCP1) as novel prognostic marker in AML
Q93059414	Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia
Q36678141	Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study
Q53289961	Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.
Q54324221	Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells.
Q58699070	Identification of long non-coding RNA competing interactions and biological pathways associated with prognosis in pediatric and adolescent cytogenetically normal acute myeloid leukemia
Q21132375	Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia
Q39783129	Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling
Q38694866	Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.
Q35054860	Identifying the similarities and differences between single nucleotide polymorphism array (SNPa) analysis and karyotyping in acute myeloid leukemia and myelodysplastic syndromes
Q47156715	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study
Q38683676	Immune evasion by oncogenic proteins of acute myeloid leukemia
Q90239928	ImmunoPET, [64Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model
Q84661264	Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations
Q36700481	Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia
Q39140034	Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype
Q90702553	Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia Patients
Q95725155	Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases
Q39040937	Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT.
Q90911358	Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation
Q89483800	Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML
Q42573844	Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.
Q40216218	Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia
Q46169540	Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia
Q40957638	Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations
Q36216242	Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia
Q48312577	Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia.
Q50561478	Impact of chemotherapy delay on short- and long-term survival in younger and older AML patients: a Danish population-based cohort study.
Q47903276	Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT.
Q84379433	Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation
Q90316154	Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype
Q38772230	Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia
Q43616985	Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML.
Q42724137	Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse
Q41176272	Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy
Q53132420	Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Pa
Q44140205	Impact of pre-transplant disease burden on the outcome of allogeneic hematopoietic stem cell transplant in refractory and relapsed acute myeloid leukemia: a single-center study
Q53114550	Impact of pre-transplant marrow blasts on survival of allogeneic stem cell transplantation in adult acute myeloid leukemia.
Q92890451	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML
Q33646183	Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
Q50923400	Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.
Q44242756	Impact of the revised International Prognostic Scoring System on the outcome of patients with acute myeloid leukemia with or without antecedent myelodysplastic syndrome
Q49566124	Improved outcome for AML patients over the years 2000-2014.
Q85217276	Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study
Q27336142	Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis
Q35179674	Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University Hospital.
Q39023971	In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediator
Q37701604	In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia
Q37014257	In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche
Q41051992	Incidence and outcomes for adults diagnosed with acute myeloid leukemia in the north of England: a real world study
Q89935888	Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group
Q40353774	Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry.
Q37621352	Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience
Q54653299	Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia.
Q51772195	Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia.
Q47137669	Inclusion and response criteria for clinical trials in relapsed/refractory acute lymphoblastic leukemia and usefulness of historical control trials
Q64261228	Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients
Q36022862	Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP.
Q51068076	Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.
Q39683672	Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia
Q40011579	Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia
Q38760193	Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials
Q36967098	Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party
Q90449425	Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis
Q33881750	Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia
Q49972906	Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.
Q37590227	Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009.
Q37226494	Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia
Q90999919	Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor
Q36862461	Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse
Q40098547	Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial
Q36450186	Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia
Q38989349	Inhibition of FLT3 in AML: a focus on sorafenib
Q41965978	Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress
Q33731216	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population
Q41335421	Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia
Q39053372	Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity
Q51139025	Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target.
Q41916176	Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model
Q41924355	Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy.
Q42149280	Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.
Q95846594	Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia
Q39113916	Integrating genomics into prognostic models for AML.
Q46606851	Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia.
Q36326271	Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
Q35596909	Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia
Q84948796	Intensity of conditioning for allogeneic haemopoetic cell transplantation
Q44507926	Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure
Q53099469	Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS).
Q37552031	Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification
Q33840247	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
Q37294760	Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells
Q35859212	International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Q37437166	Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
Q54213024	Investigation of a novel biomarker, neuropilin-1, and its application for poor prognosis in acute myeloid leukemia patients.
Q53469467	Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant.
Q33935391	Isolated extramedullary breast relapses in inv(16) positive and c-KIT negative acute myeloid leukemia after allogenic hematopoietic stem cell transplantation - description of two cases
Q30433257	Isolated gastric myeloid sarcoma: a case report and review of the literature
Q35167878	Isolated primary intracranial myeloid sarcoma with neuromeningeal infiltration: A case report
Q39190900	JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia
Q46137752	Jagged-1: a new promising factor associated with favorable prognosis in patients with acute myeloid leukemia.
Q42371609	KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia
Q36548075	Karyotype complexity and prognosis in acute myeloid leukemia
Q40575708	Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy
Q36761796	Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients
Q41870967	Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents
Q46523865	Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine
Q82675574	Landscape of TET2 mutations in acute myeloid leukemia
Q38042705	Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia
Q38060223	Leukaemias into the 21st century: part 1: the acute leukaemias
Q40537124	Leukapheresis in patients newly diagnosed with acute myeloid leukemia
Q38537725	Leukemia diagnosis: today and tomorrow
Q38382105	Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias
Q54582393	Leukemia-associated antigens are immunogenic and have prognostic value in acute myeloid leukemia.
Q33558780	Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia
Q50447093	Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens.
Q89158621	Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia
Q91793988	Liquid biopsy for minimal residual disease detection in leukemia using a portable blast cell biochip
Q40261211	Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.
Q50555238	Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis.
Q34233639	Long-term follow-up of cytogenetically normal CEBPA-mutated AML
Q40831363	Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood an
Q45254762	Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.
Q39361086	Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia.
Q37224591	Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.
Q30313615	Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
Q53110546	Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34+ Acute Myeloid Leukemia.
Q24186270	Low dose cytarabine monotherapy for acute myeloid leukaemia
Q24234680	Low dose cytarabine monotherapy for acute myeloid leukaemia
Q35794120	Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia
Q84365762	Low number of invariant NKT cells is associated with poor survival in acute myeloid leukemia
Q56974946	Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients
Q61445094	Lung resistance-related protein (LRP) predicts favorable therapeutic outcome in Acute Myeloid Leukemia
Q94570182	Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a 'Real-Life' Study
Q38862452	MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
Q34386922	MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia
Q37688200	MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells
Q40421685	MN1 and PTEN gene expression in acute myeloid leukemia.
Q92512942	MRD in AML: The Role of New Techniques
Q37606183	MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells
Q88675410	MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism
Q37457356	MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia
Q41509184	Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia
Q30249246	Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials
Q37558778	Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).
Q90053596	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study
Q36121885	Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT
Q33925386	Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia.
Q93158360	Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Q34618635	Mechanisms of cyclic nucleotide phosphodiesterases in modulating T cell responses in murine graft-versus-host disease
Q64108876	Mechanisms of drug resistance in acute myeloid leukemia
Q46576832	Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort.
Q38628894	Mesenchymal stromal cells contribute to quiescence of therapy resistant leukemic cells in acute myeloid leukemia.
Q34673820	Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia
Q47862030	Methods of Detection of Measurable Residual Disease in AML.
Q52655669	MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia.
Q41908916	MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status
Q57058463	MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy
Q91940133	MiR-9 functions as a tumor suppressor in acute myeloid leukemia by targeting CX chemokine receptor 4
Q43850689	MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.
Q36882358	MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia.
Q64892224	MicroRNA-425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy.
Q33607590	MicroRNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells
Q36511384	MicroRNA-mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients
Q38712298	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Q54275690	Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete re
Q28073464	Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
Q37016999	Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission
Q39505206	Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis
Q38494659	Minimal residual disease in acute myeloid leukemia--current status and future perspectives
Q33815986	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Q33422405	Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Q50858174	Mitochondrial cytochrome c oxidase subunit II variations predict adverse prognosis in cytogenetically normal acute myeloid leukaemia.
Q40703300	Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse
Q47164457	Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT.
Q37266555	Mobilization of CD34(+)CD38(-) hematopoietic stem cells after priming in acute myeloid leukemia
Q47108992	Modeling Myeloid Malignancies Using Zebrafish.
Q26799606	Molecular Genetic Markers in Acute Myeloid Leukemia
Q38694679	Molecular and cytogenetic abnormalities in acute myeloid leukemia: review and case studies
Q37809866	Molecular diagnosis of acute myeloid leukemia
Q37082659	Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks
Q38026007	Molecular markers in acute myeloid leukaemia
Q38989476	Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia
Q26998811	Molecular prognostic factors in cytogenetically normal acute myeloid leukemia
Q33978907	Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse
Q33925672	Molecular therapy for acute myeloid leukaemia
Q38636162	Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Q26770394	Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies
Q43879358	Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis
Q47745405	Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease
Q39235100	Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia
Q45176487	Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients
Q37079033	Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT
Q39276603	Monosomal karyotype in myeloid neoplasias: a literature review
Q38212956	Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future
Q33401766	Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia
Q40725017	Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy.
Q57786919	Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1
Q35862717	Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Q90744801	Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome
Q85521108	Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia
Q37592204	Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogene
Q54185559	Mutant Enrichment with 3'-Modified Oligonucleotides (MEMO)-Quantitative PCR for Detection of NPM1 Mutations in Acute Myeloid Leukemia.
Q42143971	Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia
Q37316165	Mutation of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic features
Q88878953	Mutation profiling of 16 candidate genes in de novo acute myeloid leukemia patients
Q37688148	Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations
Q64124189	Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia
Q35102301	Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways
Q39027793	Mutations in AML: prognostic and therapeutic implications
Q37995804	Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases
Q48267407	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.
Q38703904	Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
Q35687895	Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report
Q34347935	Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia
Q41465409	Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response
Q64265730	Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy
Q39443070	Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors
Q50976585	Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15.
Q33354547	Myeloid neoplasias: what molecular analyses are telling us
Q35079660	Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor
Q36618933	NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Q41472587	NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia
Q47112939	NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML.
Q46679237	NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells
Q57387681	NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome
Q91963132	Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia
Q33734571	Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
Q64937338	Natural Products and Acute Myeloid Leukemia: A Review Highlighting Mechanisms of Action.
Q51600879	Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.
Q34255206	Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation
Q51025557	Network-based sub-network signatures unveil the potential for acute myeloid leukemia therapy.
Q38064808	Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor
Q60357919	New drugs in acute myeloid leukemia
Q37418318	New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.
Q41891342	New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapy
Q41881090	New treatments and strategies in acute myeloid leukemia
Q58001836	Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms
Q64118224	Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?
Q27690776	Next generation sequencing of acute myeloid leukemia: influencing prognosis
Q27853094	Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations
Q64242611	Non-acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17)
Q36368289	Non-leukemic myeloid sarcoma involving the vulva, vagina, and cervix: a case report and literature review
Q39596000	Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia
Q38420779	Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant
Q36603527	Notch pathway activation targets AML-initiating cell homeostasis and differentiation
Q28075654	Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia
Q53633307	Novel STAT5B-RARA fusion transcript in acute promyelocytic leukemia: identification and treatment response.
Q38664735	Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?
Q28646898	Novel ZEB2-BCL11B Fusion Gene Identified by RNA-Sequencing in Acute Myeloid Leukemia with t(2;14)(q22;q32)
Q84831447	Novel agents in acute myeloid leukemia
Q37259702	Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity.
Q28069889	Novel therapeutic options in Acute Myeloid Leukemia
Q96643266	Novel treatment paradigms in acute myeloid leukemia
Q89768685	Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia
Q34979564	Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission
Q52892987	Omacetaxine mepesuccinate for the treatment of leukemia.
Q40314122	Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia
Q38534501	Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor
Q41336256	Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature.
Q28084813	Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
Q92593944	Oral targeted agent versus chemotherapy in acute myeloid leukaemia
Q92572394	Outcome and Prognostic Factors of High-Risk Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
Q39252132	Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Q33435191	Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia
Q52938002	Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations.
Q39036994	Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8.
Q41663607	Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML).
Q36400942	Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations
Q45340990	Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia
Q49733444	Outcomes after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia harboring t(7;11)(p15;p15).
Q47751424	Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit
Q91829180	Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission
Q41983363	Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups
Q93112984	Outcomes of Intensive Treatment of Adult Acute Myeloid Leukemia Patients: A Retrospective Study From a Single Centre
Q50137423	Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia.
Q33734101	Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Q89779300	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome
Q35018552	Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study
Q34418965	Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia
Q36771874	Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia
Q28482247	Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction
Q35130976	Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia
Q34877897	Overexpression of primary microRNA 221/222 in acute myeloid leukemia
Q34124919	P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
Q37037268	Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.
Q38835113	Panobinostat for the treatment of acute myelogenous leukemia
Q53133815	Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia.
Q35836470	Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells
Q35003602	Patient Activation through Counseling and Exercise--Acute Leukemia (PACE-AL)--a randomized controlled trial.
Q36117062	Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
Q48247115	PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia
Q38426552	Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines.
Q41948692	Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation.
Q42365051	Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy
Q37338371	Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia
Q50355902	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Q35096486	Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate.
Q38154339	Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing
Q38428692	Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
Q35286194	Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study
Q37386171	Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia
Q46769583	Pharmacometabolomics identifies dodecanamide and leukotriene B4 dimethylamide as a predictor of chemosensitivity for patients with acute myeloid leukemia treated with cytarabine and anthracycline
Q34754350	Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias
Q33437309	Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia
Q89534004	Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
Q53389797	Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.
Q88548733	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms
Q93114776	Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
Q90642732	Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia
Q36680199	Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
Q37362705	Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia
Q42417074	Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia
Q33412609	Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia
Q83255595	Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia
Q64915559	Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia.
Q36467485	Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia
Q59315342	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in O
Q27852623	Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
Q37282330	Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age.
Q35930622	Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
Q92890311	Phenylhexyl isothiocyanate suppresses cell proliferation and promotes apoptosis via repairing mutant P53 in human myeloid leukemia M2 cells
Q33956990	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
Q38380625	Plasma cell leukemia: from biology to treatment
Q34411659	Polymorphisms in XPC provide prognostic information in acute myeloid leukemia
Q35952449	Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia
Q41646967	Polymorphisms of Toll-like receptors (TLR2 and TLR4) are associated with the risk of infectious complications in acute myeloid leukemia
Q51395611	Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.
Q41930487	Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia
Q99574646	Post-remission Therapy with Repeated Courses of High Dose Cytarabine, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favorable and Intermediate-Risk AML
Q26995867	Post-remission therapy for acute myeloid leukemia
Q40190632	Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis
Q36528379	Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
Q27851805	Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis
Q36797201	Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML
Q38855427	Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis
Q37072126	Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia
Q64270574	Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia
Q39474999	Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia
Q50883085	Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia.
Q33458896	Precision oncology for acute myeloid leukemia using a knowledge bank approach
Q49534332	Precision therapy for acute myeloid leukemia.
Q37707078	Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia
Q34390721	Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation
Q39233284	Predicting Chemotherapy Resistance in AML.
Q35343940	Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes
Q35565648	Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment
Q38448204	Predictive factors for rapid neutrophil and platelet engraftment after allogenic peripheral blood stem cell transplantation in patients with acute leukemia
Q40525341	Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation
Q90788426	Predictors of short-term and long-term mortality in critically ill patients admitted to the intensive care unit following allogeneic stem cell transplantation
Q53626513	Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.
Q37270982	Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
Q41114465	Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
Q38963204	Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype.
Q33877213	Primary refractory acute myeloid leukaemia - in search of better definitions and therapies
Q41528711	Primetime for chemotherapy in acute myeloid leukemia
Q38244524	Profile of pacritinib and its potential in the treatment of hematologic disorders
Q89170844	Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association
Q38263126	Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors
Q36006412	Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission
Q26771740	Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Q40370775	Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation
Q65002747	Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience.
Q55003767	Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis
Q35152173	Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia
Q38183943	Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.
Q34119417	Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.
Q53362481	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes.
Q33558123	Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group
Q36505822	Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation
Q40359787	Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation
Q87729487	Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning
Q37467919	Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response
Q38289289	Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.
Q54355087	Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia.
Q37817621	Prognostic markers for myeloid neoplasms: a comparative review of the literature and goals for future investigation
Q36852251	Prognostic markers in AML: focus on CBFL
Q50042376	Prognostic relevance of DNMT3A R882 mutations in AML patients undergoing non-myeloablative conditioning hematopoietic stem cell transplantation.
Q45206762	Prognostic risk score for the survival of elderly patients with acute myeloid leukaemia comprising comorbidities
Q34273628	Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation
Q44000070	Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia
Q34635511	Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association
Q27853004	Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
Q30248904	Prognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies
Q36439908	Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis
Q41847123	Prognostic significance of NPM1 mutations in acute myeloid leukemia: A meta-analysis
Q38187680	Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis
Q35540475	Prognostic significance of diagnosed WT1 level in acute myeloid leukemia: a meta-analysis
Q34477821	Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Q43599101	Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission
Q41321988	Prognostic significance of high GFI1 expression in AML of normal karyotype and its association with a FLT3-ITD signature.
Q35690315	Prognostic significance of the BAALC gene expression in adult patients with acute myeloid leukemia: A meta-analysis
Q36457184	Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia
Q37160073	Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia
Q40219910	Prognostic value of brain and acute leukemia cytoplasmic gene expression in egyptian children with acute myeloid leukemia
Q47805959	Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia
Q27024006	Progress in acute myeloid leukemia
Q38095115	Prophylactic use of granulocyte colony-stimulating factor after consolidation therapy with high-dose cytarabine for acute myeloid leukemia
Q50928096	Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.
Q35640339	Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1
Q47109059	Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair
Q90462212	Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia
Q37427667	Proven invasive pulmonary mucormycosis successfully treated with amphotericin B and surgery in patient with acute myeloblastic leukemia: a case report
Q91272581	Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres
Q92688206	Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy
Q36022521	Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length
Q64066440	Quizartinib (AC220): a promising option for acute myeloid leukemia
Q42979759	RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease
Q36036605	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT
Q40531872	RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML.
Q27851839	RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures
Q27853381	RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features
Q28597831	RUNX1 truncation resulting from a cryptic and novel t(6;21)(q25;q22) chromosome translocation in acute myeloid leukemia: A case report
Q61755948	Radionuclide Therapy of Leukemias and Multiple Myeloma
Q51336746	Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study.
Q90569027	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Q36709001	Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia
Q36366636	Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
Q47730914	Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia
Q91387208	Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
Q64075116	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML
Q60300719	Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Q34106830	Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Q89673632	Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia
Q54283212	Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia.
Q44365229	Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia
Q51765662	Rapid remineralization of multiple disseminated bone lesions after high-dose cytarabine in a patient with isolated myeloid sarcoma.
Q33779805	Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Q89303143	Re-induction chemotherapy using FLAG-mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates
Q92441402	Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy
Q34082437	Recent advances in the treatment of acute myeloid leukemia.
Q42149211	Recent developments in management of older patients with acute myeloid leukemia
Q38194465	Recent discoveries in molecular characterization of acute myeloid leukemia
Q34069811	Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808
Q89770340	Recommendations for reporting post-transplant relapse in AML
Q28553650	Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors
Q38760676	Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia
Q33680186	Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemia
Q40494657	Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies
Q86046493	Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML
Q50050273	Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
Q34463645	Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies
Q54350933	Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia.
Q45394555	Refining the diagnosis and prognostic categorization of acute myeloid leukemia patients with an integrated use of cytogenetic and molecular studies
Q52374880	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Cente
Q37611616	Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia
Q52770446	Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia.
Q39260268	Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML
Q48305045	Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.
Q53196555	Renaissance of autologous stem cell transplantation for AML?
Q55076495	Reporting guidelines for oncology research: helping to maximise the impact of your research.
Q53506939	Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia.
Q34310186	Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Q48272510	Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.
Q41816813	Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome
Q35054435	Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.
Q38183872	Response evaluation and monitoring of multiple myeloma
Q52719818	Response of Myeloid Leukemia Cells to Luteolin is Modulated by Differentially Expressed Pituitary Tumor-Transforming Gene 1 (PTTG1) Oncoprotein.
Q46721176	Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.
Q37526840	Results of treatment of acute myeloid leukemia in central part of Iran
Q36544560	Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients
Q38270780	Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date
Q37850824	Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms
Q38686515	Review: Aberrant EVI1 expression in acute myeloid leukaemia
Q41906043	Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma
Q55310120	Risk factors for length of stay and charge per day differ between older and younger hospitalized patients with AML.
Q40971755	Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Q26771438	Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia
Q34996659	Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience
Q35781605	Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
Q90053632	Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications
Q37419265	Role of HOTAIR in the diagnosis and prognosis of acute leukemia
Q38352241	Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia
Q36597388	Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia
Q90274839	Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance
Q42683573	Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy
Q34144877	Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples
Q46905468	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.
Q46475052	SNAP-Tag Technology: A Promising Tool for Ex Vivo Immunophenotyping
Q38265472	STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia
Q101409830	SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism
Q98177136	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Q90200489	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia
Q90589522	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
Q34060237	Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Q41717987	Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem ce
Q37216454	Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy
Q92519522	Scalable Prediction of Acute Myeloid Leukemia Using High-Dimensional Machine Learning and Blood Transcriptomics
Q43042854	Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts
Q40542266	Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT.
Q51735777	Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation.
Q39036999	Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter study
Q38542828	Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process
Q48256316	Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL).
Q38349205	Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis
Q28087213	Secondary mutations as mediators of resistance to targeted therapy in leukemia
Q61807712	Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia
Q43649404	Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information
Q36862505	Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
Q40139200	Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
Q37555840	Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia
Q58733645	Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML
Q36294264	Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML.
Q90935240	Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?
Q54482564	Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation.
Q55163802	Sex disparity in childhood and young adult acute myeloid leukemia (AML) survival: Evidence from US population data.
Q34193514	Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm
Q36730404	Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients
Q39062973	Significance of OCT1 Expression in Acute Myeloid Leukemia.
Q37131922	Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group
Q37151698	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
Q89893024	Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes
Q35643058	Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation
Q48144263	Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie C
Q53590608	Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.
Q37580273	Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers
Q37432049	Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype
Q92668893	Somatostatin receptor mediated targeting of acute myeloid leukemia by photodynamic metal complexes for light induced apoptosis
Q54113908	Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship.
Q54363283	Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
Q91920608	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia
Q33598706	Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia
Q54475024	Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia.
Q40125142	Spectrum of mucocutaneous manifestations in an Asian cohort of patients with leukemia.
Q33394612	Spotlight on histamine dihydrochloride in acute myeloid leukaemia
Q41140906	Stanniocalcin1 gene expression in patients with acute leukemia: impact on response to therapy and disease outcome.
Q26765858	Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia
Q90341632	Stenotrophomonas maltophilia colonization during allogeneic hematopoietic stem cell transplantation is associated with impaired survival
Q88012749	Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study
Q42429593	Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT.
Q96304648	Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia
Q40961845	Successful haploidentical stem cell transplantation with prophylactic administration of liposomal amphotericin B after invasive pulmonary zygomycosis.
Q40170336	Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report
Q48025011	Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases
Q39449424	Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study
Q98164451	Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients
Q45042500	Symptom Management and Psychosocial Needs of Adults With Acute Myeloid Leukemia During Induction Treatment: A Pilot Study.
Q38691792	Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia
Q42265653	Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation
Q49780236	Systematic review of health state utility values for acute myeloid leukemia.
Q37272020	T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
Q41138074	T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.
Q33566938	TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population
Q27851621	TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study
Q35082536	TET2 mutations in secondary acute myeloid leukemias: a French retrospective study
Q89967170	THBS1 Is a Novel Serum Prognostic Factors of Acute Myeloid Leukemia
Q34320769	TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo
Q40245483	TNF as marker of oral candidiasis, HSV infection, and mucositis onset during chemotherapy in leukemia patients.
Q27853319	TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation
Q50450550	TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Q36356216	TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia
Q44772522	Tailored central nervous system-directed treatment strategy for isolated CNS recurrence of adult acute myeloid leukemia
Q46213367	Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia
Q44826618	Tailoring sparse multivariable regression techniques for prognostic single-nucleotide polymorphism signatures
Q35750567	Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions
Q47100599	Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.
Q57740688	Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure
Q47965108	Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Q64901561	Targeted therapies in the treatment of adult acute myeloid leukemias: current status and future perspectives.
Q33829283	Targeting CD157 in AML using a novel, Fc-engineered antibody construct
Q61815346	Targeting FLT3 mutations in AML: review of current knowledge and evidence
Q52375473	Targeting Leukemia Stem Cells in the Bone Marrow Niche.
Q48166242	Targeting Ras signaling in AML: RALB is a small GTPase with big potential.
Q44489428	Targeting apoptosis in acute myeloid leukaemia
Q37662400	Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia
Q38606849	Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?
Q37994256	Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?
Q36410157	Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
Q37641783	Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.
Q94603012	The 100 Most Cited Papers About Cancer Epigenetics
Q57787339	The Assessment of Left Ventricle Function and Subclinical Atherosclerosis in Patients with Acute Myeloid Leukemia
Q42024644	The Challenge of AML in Older Patients
Q43754303	The EBMT activity survey 2008: impact of team size, team density and new trends
Q28830861	The European Hematology Association Roadmap for European Hematology Research: a consensus document
Q38040708	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
Q34451619	The European LeukemiaNet: achievements and perspectives
Q33431584	The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Q64085660	The Expression of the SLIT-ROBO Family in Adult Patients with Acute Myeloid Leukemia
Q34555386	The Future of Targeting FLT3 Activation in AML.
Q43070849	The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias
Q89457595	The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia
Q36591431	The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia
Q95314923	The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C
Q34766817	The Prognostic Relevance of BAALC and ERG Expression Levels in Cytogenetically Normal Pediatric Acute Myeloid Leukemia.
Q47804815	The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.
Q37401343	The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
Q52603735	The Synonymous Isocitrate Dehydrogenase 1 315C>T SNP Confers an Adverse Prognosis in Egyptian Adult Patients with NPM1-/CEBPA-Negative Acute Myeloid Leukemia.
Q40872029	The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia
Q94299762	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study
Q26853348	The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies
Q41264435	The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia
Q27014790	The clinically relevant pharmacogenomic changes in acute myelogenous leukemia
Q37153361	The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
Q50934618	The constitutive protease release by primary human acute myeloid leukemia cells.
Q86999665	The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies
Q54273037	The detection of KIT mutations in acute myeloid leukemia.
Q45095746	The development and validation of a decision-analytic model representing the full disease course of acute myeloid leukemia
Q38482005	The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia
Q40356364	The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation
Q24187297	The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia
Q34524753	The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.
Q21284742	The epigenetic landscape of acute myeloid leukemia
Q37576054	The evolving challenge of therapy-related myeloid neoplasms
Q36254225	The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Q41141719	The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy.
Q40827250	The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
Q36564944	The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin
Q40279088	The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia
Q89776845	The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis
Q34798476	The impact of TNF superfamily molecules on overall survival in acute myeloid leukaemia: correlation with biological and clinical features.
Q48255430	The importance of FLT3 mutational analysis in acute myeloid leukemia.
Q30316611	The indications for allogeneic stem cell transplantation in myeloid malignancies
Q35691397	The influence of cytidine deaminase -33delC polymorphism on treatment outcome with high-dose cytarabine in Chinese patients with relapsed acute myeloid leukaemia
Q88551181	The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice
Q34156754	The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia
Q36544646	The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Q50044511	The molecular signature of AML with increased ALDH activity suggests a stem cell origin.
Q36619678	The myth of the second remission of acute leukemia in the adult
Q92088455	The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China
Q27693865	The prognostic and functional role of microRNAs in acute myeloid leukemia
Q35528622	The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia.
Q43566991	The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML.
Q40876342	The prognostic value of hematogones in patients with acute myeloid leukemia
Q89676365	The prognostic value of standardized phase angle in adults with acute leukemia: A prospective study
Q38211084	The role of inflammation in leukaemia
Q83363712	The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse
Q37924989	The role of molecular genetic analysis within the diagnostic haemato-oncology laboratory
Q39027087	The role of the proteasome in AML.
Q35148107	The role of therapeutic leukapheresis in hyperleukocytotic AML.
Q38760822	The safety of treatment options for elderly people with acute myeloid leukemia
Q44804404	The state of the union on treatment of acute myeloid leukemia
Q35673578	The treatment of elderly patients with acute myeloid leukemia
Q38481997	The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes
Q36866323	The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia
Q41844705	Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy
Q28071427	Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs
Q37410557	Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity
Q37372832	Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results
Q38603374	Therapy-related acute myeloid leukemia following radioactive iodine treatment for thyroid cancer
Q37699158	Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
Q28071318	Therapy-related myeloid neoplasms - what have we learned so far?
Q35717790	Therapy-related myeloid neoplasms following treatment with radioiodine
Q30240431	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?
Q28386366	Therapy-related myeloid neoplasms: pathobiology and clinical characteristics
Q34121354	Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide
Q48179574	Time to response and survival in hypomethylating agent-treated acute myeloid leukemia
Q49840237	Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.
Q41879404	To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision
Q38104287	To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century
Q90177565	Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial
Q48568919	Toward a better management of older patients with acute myeloid leukemia.
Q40705792	Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemia
Q33440695	Translational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor
Q38235586	Translational implications of somatic genomics in acute myeloid leukaemia.
Q38419355	Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AM
Q89777137	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis
Q83834636	Treatment and prophylaxis of hematologic malignancy in the central nervous system
Q26799609	Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients
Q35591409	Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia
Q39112940	Treatment of Elderly Patients With Acute Myeloid Leukemia
Q39263229	Treatment of de novo acute myeloid leukemia in the United States: a report from the Patterns of Care program.
Q82735483	Treatment of older patients with acute myeloid leukaemia
Q47796166	Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience
Q41564670	Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.
Q40727176	Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.
Q90671631	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, ph
Q38782715	Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).
Q38552664	Twist as a new prognostic marker in hematological malignancies.
Q44890063	Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia
Q26751011	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells
Q37865545	Unfavorable-risk cytogenetics in acute myeloid leukemia
Q35885311	Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity
Q54212475	Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.
Q40199108	Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission.
Q36125603	Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the A
Q36951705	Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research
Q48272424	Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission.
Q35849255	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
Q41894404	Update on optimal management of acute myeloid leukemia
Q26749006	Use of Flow Cytometry in Clinical Practice
Q26784052	Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics
Q28390558	Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia
Q35198983	Utility of transmission electron microscopy in small round cell tumors
Q63213733	Utilization Management of Genetic Testing
Q90776364	Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
Q53275620	Validation of 2 Prognostic Models in Hospitalized Patients With Advanced Hematological Malignancies in Japan.
Q38760619	Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling.
Q90304391	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes
Q37422385	Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation.
Q95942095	Validation of the Functional Assessment of Cancer Therapy-Leukemia instrument in patients with acute myeloid leukemia who are not candidates for intensive therapy
Q36161529	Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia
Q40274934	Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine
Q47660404	Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment
Q37955710	Vascular access devices in leukemia: a retrospective review amongst patients treated at the Ottawa Hospital with induction chemotherapy for acute leukemia
Q26801131	Volasertib for AML: clinical use and patient consideration
Q38221687	Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development
Q37824712	Vorinostat in acute myeloid leukemia and myelodysplastic syndromes
Q39342733	Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape
Q36770191	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Q39416207	Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?
Q39116969	What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?
Q40250091	What Is the Clinical Utility of Repeat SNP Array Testing in the Follow-up of Myeloid Neoplasms?: A Retrospective Analysis of 44 Patients With Serial SNP Arrays
Q59133388	When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
Q90028979	When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
Q52684796	Widespread use of measurable residual disease in acute myeloid leukemia practice.
Q54367385	Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT.
Q26998971	You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia
Q42265722	ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Q53365037	[Acute leukemia in adults].
Q86954339	[Acute myeloid leukemia]
Q49817229	[Allogeneic hematopoietic stem cell transplantation for treatment of refractory and relapsed acute myeloid leukemia: outcomes and prognostic factors].
Q53059589	[Analyses of outcome and prognostic factors of adult acute myeloid leukemia patients received autologous hematopoietic stem cell transplantation].
Q91911514	[Cancer patients in operative intensive care medicine]
Q49722419	[Cancer patients in operative intensive care medicine].
Q53961483	[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017)].
Q89097370	[Clinical characteristics and prognosis of 35 patients with therapy-related hematological neoplasms]
Q53550519	[Comparison of 10 mg/m² or 8 mg/m² idarubicin plus cytarabine regimen as induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia].
Q49817238	[Efficacy and safety of IA regimen containing different doses of idarubicin in de-novo acute myeloid leukemia for adult patients].
Q89319220	[How I treat acute myeloid leukemia with t (8;21)]
Q53138689	[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Q52889701	[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Q50737628	[Prognostic significance of blood count at the time of achieving morphologic leukemia-free state in adults with acute myeloid leukemia].
Q50882260	[Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Q83629936	[Risk-adapted therapy in acute myeloid leukemia]
Q49792052	[The study of expression and prognostic value of CD123 in acute myeloid leukemia bone marrow blasts].
Q56962214	acute myeloid leukemia: are we always dealing with a high-risk disease?
Q42722748	inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice
Q38871451	lncRNA co-expression network model for the prognostic analysis of acute myeloid leukemia
Q35837541	miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death.
Q92715065	miR-126 promotes the growth and proliferation of leukemia stem cells by targeting DNA methyltransferase 1
Q89574008	miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential
Q36100455	miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia
Q48336259	miR-9 is a tumor suppressor in pediatric AML with t(8;21).
Q47375547	microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview
Q34412198	α-Tomatine-mediated anti-cancer activity in vitro and in vivo through cell cycle- and caspase-independent pathways

scholarly article	Q13442814
review article	Q7318358

P356	DOI	10.1182/BLOOD-2009-07-235358
P3181	OpenCitations bibliographic resource ID	455084
P698	PubMed publication ID	19880497
P5875	ResearchGate publication ID	38058746

P50	author	Clara D. Bloomfield	Q4793409
		Pierre Fenaux	Q30170095
		Richard A. Larson	Q41899936
		Miguel A Sanz	Q54544774
		Sergio Amadori	Q56724874
		Hartmut Döhner	Q66385451
		Frederick R. Appelbaum	Q75025725
		Dietger Niederwieser	Q88402151
		Elihu Estey	Q96145785
P2093	author name string	Bob Löwenberg
		Martin S Tallman
		David Grimwade
		Alan K Burnett
		Tomoki Naoe
		Hervé Dombret
		Gert J Ossenkoppele
		Francesco Lo-Coco
		European LeukemiaNet
		Thomas Büchner
		Jorge Sierra
P433	issue	3
P407	language of work or name	English	Q1860
P921	main subject	leukemia	Q29496
		diagnosis	Q16644043
		acute myeloid leukemia	Q264118
P304	page(s)	453-474
P577	publication date	2009-10-30
P1433	published in	Blood	Q885070
P1476	title	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
P478	volume	115

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

scientific article (publication date: 30 October 2009)

Reverse relations